Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Hikma Pharmaceuticals PLC HIK shares inched up 0.88% to £19.53 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to ...

Aug 27 (Reuters) - Drug companies Jazz (JAZZ.O), opens new tab and Hikma (HIK.L), opens new tab must face claims that they schemed to delay a generic version of Jazz’s blockbuster narcolepsy ...

Hikma has completed its acquisition of Xellia Pharmaceuticals’ U.S. finished dosage form business and related assets following clearance under applicable U.S. antitrust laws. The acquisition ...

Investing.com -- Shares of Hikma Pharmaceuticals (LON:HIK) jumped on Thursday after the company raised its full-year guidance ...

Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial. Clindamycin in 5% dextrose injection is indicated for ...

Hikma Pharmaceuticals PLC HIK shares inched up 0.82% to £19.77 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0.35% ...

Worldcategory Dechra, Hikma, M&S and Diploma set to join FTSE 100 August 23, 2023 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics ...

Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. Earl L. "Buddy" Carter of Georgia ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...